Expression of Cyclin D1 in Hyperplasia and Carcinoma of Endometrium and Its Correlation with Histologic Grade, Tumor Type, and Clinicopathological Features

Abstract

Background Endometrial carcinoma is often preceded by characteristic histopathologic lesions known as endometrial hyperplasia. Estrogen, p53, PTEN, and overexpression of cyclin D1 appear to be involved in the development of endometrial carcinogenesis.

Design We evaluated and compared the expression profile of cyclin D1 expressions in 50 endometrial samples submitted as either endometrial curetting (n = 34) or hysterectomy (n = 16) specimens, which were diagnosed as simple hyperplasia (n = 10), complex hyperplasia (n = 06), atypical hyperplasia (n = 04), and endometrial carcinoma (n = 20). Ten cases of normal proliferative and secretory endometrium were selected as controls. Breast cancer with known cyclin D1 expression was selected as a positive control in each immunohistochemistry run.

Results Cyclin D1 was significantly overexpressed in glands with complex hyperplasia and endometrial adenocarcinoma compared with proliferative or secretory endometrium and simple hyperplasia. A statistical difference was found in the extent of cyclin D1 positivity of simple hyperplasia and carcinoma of the endometrium (p < 0.005). No statistical difference was seen between complex hyperplasia and carcinoma and clinicopathologic parameters in endometrioid carcinomas. All cases of clear cell carcinoma and serous carcinoma showed cyclin D1 immunoreactivity. Significant statistical difference was seen between cyclin D1 expression and only one clinicopathologic parameter, i.e., menopausal status in endometrial carcinomas

Conclusion Cyclin D1 over expression may be an early event in endometrial carcinogenesis and cyclin D1 over expression may be an informative biomarker to recognize subsets of endometrial lesions that may be precancerous and therefore amenable to surgical therapy.

Keywords

carcinoma - cyclin D1 - endometrium - hyperplasia - immunohistochemistry

• References

• 1 Silverberg SG, Kurman RJ. Tumors of the uterine corpus and gestational trophoblastic disease. Atlas of Tumor Pathology: Third series, Fascicle 3. Washington, DC: Armed Forces Institute of Pathology; 1992: 290
• 2 Wang Y, Zhu JF, Liu YY, Han GP. An analysis of cyclin D1, cytokeratin 5/6 and cytokeratin 8/18 expression in breast papillomas and papillary carcinomas. Diagn Pathol 2013; 8: 8
• 3 Shawana S, Kehar SI, Masood S, Aamir I. Immunoexpression of cyclin D1 and PTEN in various endometrial pathologies. J Coll Physicians Surg Pak 2016; 26 (04) 277-282
• 4 Wu W, Slomovitz BM, Soliman PT. et al. Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma. Int J Gynecol Cancer 2006; 16 (04) 1668-1672
• 5 Abu-Rustum NR, Zhou Q, Iasonos A. et al. The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered?. Int J Gynecol Cancer 2011; 21 (03) 511-516
• 6 Gayther SA, Pharoah PD. The inherited genetics of ovarian and endometrial cancer. Curr Opin Genet Dev 2010; 20 (03) 231-238
• 7 Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15 (01) 10-17
• 8 Sun Y, Luo D, Liao DJ. Cyclin D1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-MB231 cells. J Carcinog 2012; 11 (01) 12
• 9 Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13 (12) 1501-1512
• 10 Ruhul Quddus M, Latkovich P, Castellani WJ. et al. Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis. Arch Pathol Lab Med 2002; 126 (04) 459-463
• 11 Özuysal S, Oztürk H, Bilgin T, Filiz G. Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables. Arch Gynecol Obstet 2005; 271 (02) 123-126
• 12 Choudhury M, Bansal S. Expression of cyclin D1 in endometrial hyperplasia and endometrial carcinoma. Indian J Pathol Microbiol 2007; 50 (04) 708-710
• 13 Liang S, Mu K, Wang Y. et al. Cyclin D1, a prominent prognostic marker for endometrial diseases. Diagn Pathol 2013; 8: 138
• 14 Stewart CJR, Crook ML, Leung YC, Platten M. Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumor areas and in microcystic, elongated and fragmented glands. Mod Pathol 2009; 22 (05) 725-733
• 15 Shevra CR, Ghosh A, Kumar M. Cyclin D1 and Ki-67 expression in normal, hyperplastic and neoplastic endometrium. J Postgrad Med 2015; 61 (01) 15-20
• 16 Kala M, Gill M, Gupta V, Srivastava D, Tanwar P, Goyal V. Cyclin D1 expression in hyperplasia and carcinoma of the endometrium and its correlation with histologic grade and tumor type. J Gynecol Surg 2014; 30 (01) 1-4
• 17 Nishimura Y, Watanabe J, Jobo T. et al. Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis. Anticancer Res 2004; 24 (04) 2185-2191
• 18 Khabaz MN, Abdelrahman AS, Butt NS, Al-Maghrabi B, Al-Maghrabi J. Cyclin D1 is significantly associated with stage of tumor and predicts poor survival in endometrial carcinoma patients. Ann Diagn Pathol 2017; 30: 47-51